The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging.
作者信息
Eder Ann-Christin, Omrane Mohamed A, Stadlbauer Sven, Roscher Mareike, Khoder Wael Y, Gratzke Christian, Kopka Klaus, Eder Matthias, Meyer Philipp T, Jilg Cordula A, Ruf Juri
机构信息
Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany.
出版信息
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2057-2058. doi: 10.1007/s00259-020-05184-0. Epub 2021 Jan 23.
Abstract
摘要
相似文献
1
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging.源自PSMA-11的杂交分子PSMA-914通过术前PET/CT和术中荧光成像特异性识别前列腺癌。
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2057-2058. doi: 10.1007/s00259-020-05184-0. Epub 2021 Jan 23.
2
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用：系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
3
Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?在高危前列腺癌患者的初始分期中，添加骨骼成像到 68-Ga-前列腺特异性膜抗原-PET/CT 是否有用？
Nucl Med Commun. 2020 Nov;41(11):1183-1188. doi: 10.1097/MNM.0000000000001268.
4
Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.镓-PSMA-11 PET/CT 在复发性前列腺癌中的应用：根治性治疗后 PSA 失败不同临床阶段的疗效。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.
5
Gallium-68-prostate-specific membrane antigen ( Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.镓-68-前列腺特异性膜抗原（Ga-PSMA）正电子发射断层扫描（PET）/计算机断层扫描（CT）可预测中高危前列腺癌根治性前列腺切除术和淋巴结清扫术后的完全生化缓解。
BJU Int. 2019 Jul;124(1):62-68. doi: 10.1111/bju.14506. Epub 2019 Apr 7.
6
Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.术前 Ga-68 PSMA-11 PET-CT 和 mp-MRI 结果与前列腺癌术后组织病理学的比较。
Prostate. 2019 Jun;79(9):1007-1017. doi: 10.1002/pros.23812. Epub 2019 Apr 23.
7
Detection Efficacy of Hybrid Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.基于 Phoenix 标准的初程放疗后生化复发的前列腺癌患者中杂交 Ga-PSMA 配体 PET/CT 的检测效能。
J Nucl Med. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457. Epub 2017 Feb 16.
8
In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?在高危和中危前列腺癌患者的原发性淋巴结分期中，镓68前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描的作用有多关键？
Nucl Med Commun. 2020 Feb;41(2):139-146. doi: 10.1097/MNM.0000000000001110.
9
Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.Ga-PSMA-11 PET/CT 衍生代谢参数用于确定前列腺癌的全身肿瘤负担和治疗反应。
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872. doi: 10.1007/s00259-018-4042-z. Epub 2018 May 3.
10
Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.在 PSA 水平低于 1.0ng/ml 的 270 例患者中，Ga-PSMA-11 PET/CT 对前列腺癌根治术后生化复发的定位：对挽救性放疗计划的影响。
J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.
引用本文的文献
1
Intraoperative Confocal Laser Endomicroscopy Detects Prostate Cancer at the Single-Cell Level with High Specificity and in Real Time: A Preclinical Proof of Concept.术中共聚焦激光内镜检查在单细胞水平实时、高特异性地检测前列腺癌：一项临床前概念验证。
Pharmaceuticals (Basel). 2025 Jun 4;18(6):841. doi: 10.3390/ph18060841.
2
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.用于前列腺癌精准诊断与治疗的分子成像探针的进展。
J Zhejiang Univ Sci B. 2025 Jan 15;26(2):124-144. doi: 10.1631/jzus.B2300614.
3
Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives.癌症成像与荧光引导手术中的双标记小肽：进展与未来展望
Pharmaceuticals (Basel). 2025 Jan 22;18(2):143. doi: 10.3390/ph18020143.
4
Lessons learned in application driven imaging agent design for image-guided surgery.应用导向型影像探针设计用于影像引导手术的经验教训。
Eur J Nucl Med Mol Imaging. 2024 Aug;51(10):3040-3054. doi: 10.1007/s00259-024-06791-x. Epub 2024 Jun 20.
5
Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.前列腺特异性膜抗原靶向手术治疗前列腺癌：准确识别、实时诊断和精确切除。
Theranostics. 2024 Apr 22;14(7):2736-2756. doi: 10.7150/thno.95039. eCollection 2024.
6
Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel.德尔福共识项目关于前列腺特异性膜抗原（PSMA）靶向手术的结果-来自国际多学科小组。
Eur J Nucl Med Mol Imaging. 2024 Aug;51(10):2893-2902. doi: 10.1007/s00259-023-06524-6. Epub 2023 Nov 28.
7
State of the Art in Prostate-specific Membrane Antigen-targeted Surgery-A Systematic Review.前列腺特异性膜抗原靶向手术的研究现状——一项系统综述
Eur Urol Open Sci. 2023 Jun 16;54:43-55. doi: 10.1016/j.euros.2023.05.014. eCollection 2023 Aug.
8
Efforts toward PET-Activatable Red-Shifted Silicon Rhodamines and Silicon Pyronine Dyes.对正电子发射断层扫描（PET）可激活的红移硅罗丹明和硅派洛宁染料的研究工作。
Pharmaceuticals (Basel). 2023 Mar 7;16(3):401. doi: 10.3390/ph16030401.
9
The current status and future prospects for molecular imaging-guided precision surgery.分子影像引导下的精准手术的现状与展望。
Cancer Imaging. 2022 Sep 6;22(1):48. doi: 10.1186/s40644-022-00482-2.
10
Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.用于核与荧光分子成像的双标记策略：现状与未来展望
Pharmaceuticals (Basel). 2022 Mar 31;15(4):432. doi: 10.3390/ph15040432.
本文引用的文献
1
Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.PSMA 靶向杂合体示踪剂 PSMA-I&F 的合成及初步临床特征分析用于前列腺癌的核素及荧光成像。
J Nucl Med. 2019 Jan;60(1):71-78. doi: 10.2967/jnumed.118.212720. Epub 2018 Sep 20.
2
Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation.机器人辅助腹腔镜手术采用 DROP-IN 放射引导：首例人体翻译。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):49-53. doi: 10.1007/s00259-018-4095-z. Epub 2018 Jul 27.
3
PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.PSMA-11 衍生的双标记 PSMA 抑制剂用于前列腺癌的术前 PET 成像和精确荧光引导手术。
J Nucl Med. 2018 Apr;59(4):639-645. doi: 10.2967/jnumed.117.201293. Epub 2017 Nov 30.
4
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.（68）镓标记的前列腺特异性膜抗原（PSMA）配体HBED-CC的PET/CT成像在复发性前列腺癌诊断中的价值
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.
5
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.68Ga-配合物的亲脂性和基于脲的 PSMA 抑制剂用于 PET 成像的靶向特性。
Bioconjug Chem. 2012 Apr 18;23(4):688-97. doi: 10.1021/bc200279b. Epub 2012 Mar 13.
6
Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.前列腺癌前哨淋巴结清扫术：1000多例患者的经验
J Urol. 2007 Mar;177(3):916-20. doi: 10.1016/j.juro.2006.10.074.
Zotero 插件